The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1441-1448, December 2007

Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: Modulation by allergic status and oral corticosteroids

  • Yael Gernez, MD

      Affiliations

    • Department of Genetics, Stanford University School of Medicine, Stanford, Calif
    • These are equal first authors; they are listed alphabetically.
  • ,
  • Rabindra Tirouvanziam, PhD

      Affiliations

    • Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif
    • Corresponding Author InformationReprint requests: Rabindra Tirouvanziam, PhD, Beckman Center B013, Stanford, CA 94305-5318.
    • These are equal first authors; they are listed alphabetically.
  • ,
  • Khoa D. Nguyen, BS

      Affiliations

    • Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif
  • ,
  • Leonard A. Herzenberg, PhD

      Affiliations

    • Department of Genetics, Stanford University School of Medicine, Stanford, Calif
  • ,
  • Alan M. Krensky, MD

      Affiliations

    • Office of Director, National Institutes of Health, Bethesda, Md
  • ,
  • Kari C. Nadeau, MD, PhD

      Affiliations

    • Department of Pediatrics, Stanford University School of Medicine, Stanford, Calif

Received 13 February 2007; received in revised form 2 August 2007; accepted 6 August 2007. published online 08 October 2007.

Background

Asthma is a complex immunologic disorder linked to altered cytokine signaling.

Objective

We tested whether asthmatic patients showed any change in cytokine-dependent signal transducer and activator of transcription (STAT) levels, focusing on the central/effector-memory CD4+CD161+ subset, which represents 15% to 25% of circulating T cells.

Methods

We quantified intracellular levels of active phosphorylated STAT (phospho-STAT) 1, 3, 5, and 6 by means of flow cytometry, without any activation or expansion.

Results

Baseline phospho-STAT1 and phospho-STAT6 levels were increased in CD4+CD161+ T cells from asthmatic patients compared with those from healthy control subjects (by 10- and 8-fold, respectively). This asthma-associated alteration was both subset specific because no change was seen in CD4+CD161CD25+ (regulatory T cells) and CD4+CD161CD25 subsets and isoform specific because phospho-STAT5 and phospho-STAT3 levels were unchanged. Among asthmatic patients, phospho-STAT1 and phospho-STAT6 levels correlated negatively with each other, suggesting antagonistic regulation. Oral corticosteroid (OCS) treatment significantly decreased phospho-STAT6 and IL-4 levels but not phospho-STAT1 levels. Disease parameters showing significant correlations with phospho-STAT1, phospho-STAT6, or both included age at onset, plasma IgE levels, and levels of the TH2 cytokines IL-4 and IL-10 and the TH1 cytokine IL-2. Overall, combined phospho-STAT1 and phospho-STAT6 measurements showed excellent predictive value for identifying (1) asthmatic patients versus healthy control subjects, (2) allergic versus nonallergic asthmatic patients, and (3) asthmatic patients taking versus those not taking OCSs.

Conclusion

Baseline changes in phospho-STAT1 and phospho-STAT6 levels in blood CD4+CD161+ T cells identify asthmatic patients and mirror their allergic status and response to OCSs.

Clinical implications

These results confirm the pathologic importance of activated STAT1 and STAT6 in asthma and suggest their potential use as clinical biomarkers.

Key words: Allergy, atopy, fluorescence-activated cell sorting, immune polarization

Abbreviations used: FACS, Fluorescence-activated cell sorting, IL-4R, IL-4 receptor, NK, Natural killer, OCS, Oral corticosteroid, ROC, Receiver operating characteristic, STAT, Signal transducer and activator of transcription

 

 Supported by the Mary Hewitt Loveless Foundation, the Walter and Idun Berry Fellowship, the Parker B. Francis Foundation, and the American Association of Allergy, Asthma & Immunology Special Interest Award.

 Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01575-8

doi:10.1016/j.jaci.2007.08.012

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 6 , Pages 1441-1448, December 2007